长春西汀治疗急性冠脉综合征合并高血压的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 长春西汀治疗急性冠脉综合征合并高血压的临床观察
TITLE:
摘要: 目的:观察长春西汀治疗急性冠脉综合征(ACS)合并高血压的疗效和安全性。方法:90例ACS合并高血压患者随机分为对照组(45例)和观察组(45例)。对照组患者给予阿托伐他汀钙片20 mg,口服,每日1次+硫酸氢氯吡格雷片75 mg,口服,每日1次+苯磺酸左旋氨氯地平片2.5 mg,口服,每日1次+单硝酸异山梨酯缓释片40 mg,口服, 每日1次。观察组患者在对照组治疗的基础上给予长春西汀注射液30 mg,加入0.9%氯化钠注射液或5%葡萄糖注射液250 ml中,静脉滴注,每日1次。两组疗程均为14 d。观察两组患者的临床疗效、治疗前后收缩压(SBP)、舒张压(DBP)、心绞痛发作频率、持续时间、发作间隔时间、ST段下移、血液黏度、D-二聚体、血小板聚集率、纤维蛋白原水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者SBP、DBP、心绞痛发作频率、持续时间、发作间隔时间、ST段下移、血液黏度、D-二聚体、血小板聚集率、纤维蛋白原水平比较,差异均无统计学意义(P>0.05)。治疗后,两组患者SBP、DBP均显著低于同组治疗前,差异均有统计学意义(P<0.05),但两组间比较差异无统计学意义(P>0.05);发作频率、持续时间、ST段下移、血液黏度、D-二聚体、血小板聚集率、纤维蛋白原水平均显著低于同组治疗前,且观察组低于对照组,发作间隔时间显著长于同组治疗前,且观察组长于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论: 在常规治疗的基础上,长春西汀治疗ACS合并高血压的疗效和安全性均较好。
ABSTRACT: OBJECTIVE: To observe the efficacy and safety of vinpocetine in the treatment of acute coronary syndrome (ACS) with hypertension. METHODS: 90 patients with ACS and hypertension were randomly divided into control group (45 cases) and observation group (45 cases). Control group received Atorvastatin calcium tablet 20 mg, orally, once a day+Clopidogrel hydrogen sulfate tablet 75 mg, orally, once a day+Levamlodipine besylate tablet 2.5 mg, orally, once a day+Isosorbide mononitrate sustained-release tablet 40 mg, orally, once a day. Observation group was additionally given Vinpocetine injection 30 mg, adding into 0.9% Sodium chloride injection or 5% Glucose injection 250 ml by intravenous infusion, once a day. The 2 groups were treated for 14 d. The clinical efficacy, systolic blood pressure (SBP), diastolic blood pressure (DBP), attack frequency, duration, interval time of the attack, ST segment down, blood viscosity, D-dimer, platelet aggregation rate, fibrinogen levels before and after treatment, and the incidence of adverse reactions in 2 groups were observed. RESULTS: The total effective rate in observation group was significantly higher than control group, with statistical significance (P<0.05). Before treatment, there were no significant differences in SBP, DBP, attack frequency, duration, interval time of the attack, ST segment down, blood viscosity, D-dimer, platelet aggregation rate, fibrinogen levels in 2 groups (P>0.05). After treatment, SBP and DBP in 2 groups were significantly lower than before, with statistical significance (P<0.05), while there was no significant difference in 2 groups (P>0.05). Attack frequency, duration,ST segment down, blood viscosity, D-dimer, platelet aggregation rate, fibrinogen levels in 2 groups were significantly lower than before, and observation group was lower than control group, interval time of the attack in 2 groups was significantly long than before,and observation group was longer than control group,with statistical significances (P<0.05). And there was no significant difference in the incidence of adverse reactions in 2 groups (P>0.05). CONCLUSIONS: Based on the conventional treatment, both efficacy and safety of vinpocetine in the treatment of ACS with hypertension are good.
期刊: 2016年第27卷第33期
作者: 魏国政,邓长金
AUTHORS: WEI Guozheng,DENG Changjin
关键字: 长春西汀;急性冠脉综合征;高血压;疗效;安全性
KEYWORDS: Vinpocetine injection; Acute coronary syndrome; Hypertension; Efficacy; Safety
阅读数: 421 次
本月下载数: 1 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!